Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 9,125 shares, a decline of 49.8% from the October 15th total of 18,161 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 8,875 shares, the short-interest ratio is currently 1.0 days.
Ascentage Pharma Group International Price Performance
NASDAQ:AAPG traded down $0.10 during mid-day trading on Tuesday, reaching $13.19. 1,762 shares of the company’s stock traded hands, compared to its average volume of 6,934. Ascentage Pharma Group International has a 12-month low of $13.12 and a 12-month high of $33.09. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The company has a 50 day moving average price of $15.28 and a 200-day moving average price of $19.55.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million during the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International will post -2.43 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Tuesday. JPMorgan Chase & Co. lowered their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective for the company. Citigroup started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price on the stock. Finally, William Blair began coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $43.44.
Get Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Featured Stories
- Five stocks we like better than Ascentage Pharma Group International
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
